Omalizumab as a corticosteroid‐sparing agent in the treatment of bullous pemphigoid

Abstract Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of autoantibodies against hemidesmosomal components BP180 and BP230. The mainstay of therapy is topical and systemic corticosteroids (CS) and immunosuppressors. As this pathology...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Camilla Vassallo, Anita Somenzi, Mara De Amici, Stefania Barruscotti, Valeria Brazzelli
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2022-12-01
Edice:	Dermatologic Therapy
Témata:	bullous pemphigoid comorbidities corticosteroid‐sparing omalizumab
On-line přístup:	https://doi.org/10.1111/dth.15946
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!